Nisa Investment Advisors LLC raised its stake in shares of Celgene Corp. (NASDAQ:CELG) by 9.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 247,313 shares of the biopharmaceutical company’s stock after buying an additional 20,900 shares during the period. Nisa Investment Advisors LLC’s holdings in Celgene Corp. were worth $25,852,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Ngam Advisors L.P. raised its stake in shares of Celgene Corp. by 3.6% in the second quarter. Ngam Advisors L.P. now owns 166,196 shares of the biopharmaceutical company’s stock worth $16,392,000 after buying an additional 5,707 shares during the period. Atwood & Palmer Inc. raised its stake in shares of Celgene Corp. by 1.7% in the second quarter. Atwood & Palmer Inc. now owns 156,343 shares of the biopharmaceutical company’s stock worth $15,420,000 after buying an additional 2,543 shares during the period. Fisher Asset Management LLC raised its stake in shares of Celgene Corp. by 3.0% in the second quarter. Fisher Asset Management LLC now owns 204,128 shares of the biopharmaceutical company’s stock worth $21,109,000 after buying an additional 5,968 shares during the period. Putnam FL Investment Management Co. raised its stake in shares of Celgene Corp. by 1.4% in the second quarter. Putnam FL Investment Management Co. now owns 117,359 shares of the biopharmaceutical company’s stock worth $11,575,000 after buying an additional 1,575 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Celgene Corp. by 0.8% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,488,765 shares of the biopharmaceutical company’s stock worth $245,467,000 after buying an additional 20,006 shares during the period. 76.43% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) traded down 1.15% during mid-day trading on Wednesday, reaching $120.72. The company’s stock had a trading volume of 1,041,786 shares. The company has a market capitalization of $93.58 billion, a PE ratio of 45.85 and a beta of 1.71. The firm has a 50 day moving average price of $108.88 and a 200-day moving average price of $106.73. Celgene Corp. has a 1-year low of $93.05 and a 1-year high of $127.00.

Celgene Corp. (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.10. The business had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The business’s revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. On average, equities analysts predict that Celgene Corp. will post $5.92 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Celgene Corp. (CELG) Shares Bought by Nisa Investment Advisors LLC” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. and international copyright legislation. The correct version of this report can be accessed at http://www.dailypolitical.com/2016/11/30/celgene-corp-celg-shares-bought-by-nisa-investment-advisors-llc.html.

A number of brokerages have issued reports on CELG. Oppenheimer Holdings Inc. began coverage on shares of Celgene Corp. in a report on Tuesday. They issued an “outperform” rating and a $141.00 price target on the stock. Vetr raised shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $128.85 target price for the company in a research report on Tuesday. Cann began coverage on shares of Celgene Corp. in a research report on Monday. They issued an “outperform” rating and a $141.00 target price for the company. Standpoint Research cut shares of Celgene Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, November 9th. Finally, Mizuho began coverage on shares of Celgene Corp. in a research report on Monday, November 7th. They issued a “buy” rating and a $130.00 target price for the company. Four investment analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the stock. Celgene Corp. presently has a consensus rating of “Buy” and a consensus target price of $136.62.

In related news, Director Gilla Kaplan sold 9,710 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $106.44, for a total value of $1,033,532.40. Following the sale, the director now owns 72,142 shares of the company’s stock, valued at approximately $7,678,794.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Corp /De/ Celgene purchased 800,150 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. 0.97% of the stock is owned by corporate insiders.

Celgene Corp. Company Profile

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corp. (NASDAQ:CELG).

Receive News & Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related companies with MarketBeat.com's FREE daily email newsletter.